268 reports of this reaction
1.6% of all LAMIVUDINE AND ZIDOVUDINE reports
#15 most reported adverse reaction
OSTEOPOROSIS is the #15 most commonly reported adverse reaction for LAMIVUDINE AND ZIDOVUDINE, manufactured by ViiV Healthcare Company. There are 268 FDA adverse event reports linking LAMIVUDINE AND ZIDOVUDINE to OSTEOPOROSIS. This represents approximately 1.6% of all 16,773 adverse event reports for this drug.
Patients taking LAMIVUDINE AND ZIDOVUDINE who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPOROSIS is a less commonly reported adverse event for LAMIVUDINE AND ZIDOVUDINE, but still significant enough to appear in the safety profile.
In addition to osteoporosis, the following adverse reactions have been reported for LAMIVUDINE AND ZIDOVUDINE:
The following drugs have also been linked to osteoporosis in FDA adverse event reports:
OSTEOPOROSIS has been reported as an adverse event in 268 FDA reports for LAMIVUDINE AND ZIDOVUDINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPOROSIS accounts for approximately 1.6% of all adverse event reports for LAMIVUDINE AND ZIDOVUDINE, making it a notable side effect.
If you experience osteoporosis while taking LAMIVUDINE AND ZIDOVUDINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.